• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theralase Techs Inc (OP:TLTFF)

0.2184 +0.0096 (+4.60%)
Streaming Delayed Price Updated: 3:34 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theralase Techs Inc

< Previous 1 2 3 4 Next >
News headline image
Theralase(R) Technology Effective in Virus Inactivation
June 04, 2024
Via ACCESSWIRE
News headline image
Theralase(R) Release's 1Q2024 Financial Statements
May 30, 2024
Via ACCESSWIRE
News headline image
Theralase(R) Expands Clinical Team
May 02, 2024
Via ACCESSWIRE
News headline image
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024
Via ACCESSWIRE
News headline image
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Via ACCESSWIRE
News headline image
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
October 23, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 16, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Files US Patent for Enhanced Immunotherapy
October 05, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Via ACCESSWIRE
News headline image
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
March 26, 2024
Via ACCESSWIRE
News headline image
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
February 12, 2024
Via ACCESSWIRE
News headline image
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
February 08, 2024
Via ACCESSWIRE
News headline image
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 05, 2024
Via ACCESSWIRE
News headline image
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
January 15, 2024
Via ACCESSWIRE
News headline image
Theralase Release’s 3Q2023 Interim Financial Statements
November 29, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
November 17, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Announces Brokered LIFE Financing
October 23, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
September 29, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
September 27, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Grants Stock Options
September 21, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Closes Private Placement Equity Financing
September 07, 2023
Via ACCESSWIRE
News headline image
Theralase Release’s 2Q2023 Interim Financial Statements
August 29, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
June 30, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Announces Appointment of New Independent Director
June 06, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
May 30, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Releases 1Q2023 Interim Financial Statements
May 30, 2023
Via ACCESSWIRE
News headline image
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
May 24, 2023
Via ACCESSWIRE
News headline image
Theralase Provides Update on Phase II Bladder Cancer Study
May 10, 2023
Via ACCESSWIRE
News headline image
Theralase Release FY2020 Audited Financial Statements
April 28, 2021
TORONTO, ON / ACCESSWIRE / April 28, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and... 
From Theralase Technologies Inc.
Via AccessWire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap